D&A initially held abut 8 million shares but purchased a further 19.1 million late last month for a cash consideration of more than $5 million.
Pharmaxis is an Australian pharmaceutical research company focused on inflammation and fibrosis with a portfolio of products at various stages of development and approval.
The company’s development pipeline focuses on its expertise in amine oxidase chemistry and includes:
A series of lysyl oxidase like 2 (LOXL2) inhibitors targeting fibrotic diseases of the liver, heart, kidney and lunch that recently completed phase-one clinical trials;
A lysyl oxidase (LOX) inhibitor in development for pancreatic cancer that recently completed preclinical development; and
A potent inhibitor of semicarbazide-sensitive amine oxidase (SSAO) called BI 1467335 to develop treatment for the liver-related condition non-alcoholic steatohepatitis (NASH) and other inflammatory diseases.
Pharmaxis manufactures and exports its approved products from its facility in Sydney, including Bronchitol for the treatment of cystic fibrosis and Aridol, a lung function test for asthma.